Physician-scientist at the University of Pennsylvania. Determined to understand chronic kidney disease development
Dec 28 • 7 tweets • 3 min read
Here are 5 clinical advances from 2025 in kidney and cardiorenal medicine that clinicians across specialties should know before the year ends. These findings influence how we prevent and treat common, high-risk conditions. #MedTwitter #Nephrology
The FDA approved sibeprenlimab (Voyxact) a subcutaneous monoclonal antibody that significantly reduces proteinuria in adults with IgA nephropathy (IgAN), offering a new targeted treatment option Sibeprenlimab in IgA Nephropathy — nejm.org/doi/full/10.10…